A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma

Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Vaccines (Basel)
Auteurs principaux: Tamura, Ryota, Morimoto, Yukina, Sato, Mizuto, Hikichi, Tetsuro, Yoshida, Kazunari, Toda, Masahiro
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Communication
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7564945/
https://ncbi.nlm.nih.gov/pubmed/32887369
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8030498
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires